Thermo Fisher Scientific to produce Nucleic Acid Isolation Kits in India
The isolation kit enables highly scalable, accessible, faster and more consistent viral RNA and DNA extraction and can process up to 96 samples in 30 minutes.
Mumbai: Thermo Fisher Scientific has recently announced that the company will manufacture its Applied Biosystems MagMAX Dx Prefilled Viral/Pathogen Nucleic Acid Isolation Kits in India for the Indian market.
The kit is used to isolate and purify viral RNA and DNA from human saliva, nasopharyngeal and oral pharyngeal swabs, providing a faster, more precise and easier-to-use solution for customers.
The MagMax Dx Prefilled Viral/Pathogen Nucleic Acid Isolation Kit will be manufactured in Thermo Fisher's state-of-the-art manufacturing facility in Bengaluru. The site is currently used to produce CoviPath RT-PCR COVID-19 testing kits for customers in India.
The isolation kit is designed for use by qualified and trained clinical laboratory personnel. It has been approved for in vitro diagnostic use by the Indian Council for Medical Research (ICMR) and Drug Control General of India (DCGI).
"Thermo Fisher Scientific has played a pivotal role in the global response against COVID-19, and we have made significant investments to support our customers in India," said Amit Chopra, managing director, India and South Asia, Thermo Fisher Scientific.
"While the situation is gradually improving, the world still needs more advanced solutions that improve testing quality and sustain bulk testing with less processing time, and the MagMAX Dx Prefilled Viral/Pathogen Nucleic Acid Isolation Kit will support this effort," added Amit.
The isolation kit enables highly scalable, accessible, faster and more consistent viral RNA and DNA extraction and can process up to 96 samples in 30 minutes.
It comes with pre-filled, automation-ready media plates can be used with Kingfisher Flex instruments with special automation-ready compatibility with the Thermo Scientific Kingfisher Flex Purification System.
Read also: Thermo Fisher rolls out point-of-care RT-PCR test for Covid-19 in India
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.